Back
Ultragenyx Pharmaceutical, Inc. 10K Form
Sell
40
RARE
Ultragenyx Pharmaceutical, Inc.
Last Price:
$36.54
Seasonality Move:
8.64%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-03 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2023-11-03 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2023-08-04 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2023-05-05 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2022-11-03 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2022-07-29 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
Receive RARE News And Ratings
See the #1 stock for the next 7 days that we like better than RARE
RARE Financial Statistics
Sales & Book Value
| Annual Sales: | $560.2M |
|---|---|
| Cash Flow: | $-92.7M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.10 |
| Price / Book: | 383.95 |
Profitability
| EPS (TTM): | -5.93880 |
|---|---|
| Net Income (TTM): | $-579.8M |
| Gross Margin: | $453.5M |
| Return on Equity: | -307.83% |
| Return on Assets: | -42.32% |
Ultragenyx Pharmaceutical, Inc. Earnings Forecast
Key Ultragenyx Pharmaceutical, Inc. Financial Ratios
-
The Gross Profit Margin over the past 21 years for RARE is 80.94%.
-
The Selling, General & Administrative Expenses for RARE have been equal to 57.41% of Gross Profit Margin.
-
The Research & Development expenses have been 119.20% of Revenue.
-
The Net Earning history of RARE is -101.60% of Total Revenues.
-
Per Share Earnings over the last 21 years have been positive in 9 years.
Ultragenyx Pharmaceutical, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RARE |
| CUSIP: | 90400D |
| Website: | ultragenyx.com |
Debt
| Debt-to-Equity Ratio: | 94.24 |
|---|---|
| Current Ratio: | 1.89 |
| Quick Ratio: | 1.61 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RARE Technical Analysis vs Fundamental Analysis
Sell
40
Ultragenyx Pharmaceutical, Inc. (RARE)
is a Sell
Is Ultragenyx Pharmaceutical, Inc. a Buy or a Sell?
-
Ultragenyx Pharmaceutical, Inc. stock is rated a SellThe current Ultragenyx Pharmaceutical, Inc. [RARE] share price is $36.54. The Score for RARE is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.